Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents.

Stenberg A, Läckgren G

Pediatrics1 Dec 1994Cited by 30 (Europe PMC)

PMID7970999DOI10.1542/peds.94.6.841PepBankPUB-07970999

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In adolescents with severe nocturnal enuresis, wet nights decreased from 4.9 to 2.8 per week during desmopressin titration.
In plain wordsIn adolescents with severe bedwetting, wet nights decreased during desmopressin dose titration.
Peptide
Desmopressin
Outcome
DecreaseWet nights during dose titration
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
400 micrograms in the majority · oralAs given in this study (human).
Measurements
Wet nights
4.9 per week
baseline
Wet nights
2.8 per week
dose titration
Source sentences
Summary
During the first dose-titration period, the majority of the patients were given desmopressin 400 micrograms, and the number of wet nights decreased from a mean of 4.9 to 2.8.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099901
02HumanNon-randomized trialEfficacy outcome
In adolescents with severe nocturnal enuresis, desmopressin significantly reduced wet nights to 1.8 versus 4.1 with placebo.
In plain wordsIn adolescents with severe bedwetting, desmopressin reduced wet nights compared with placebo.
Peptide
Desmopressin
Outcome
DecreaseWet nights during crossover
Study
n: not reported in source
Comparator
Placebo
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Wet nights
1.8 per week
desmopressin
Wet nights
4.1 per week
placebo
Source sentences
Summary
During the double-blind period, a significant reduction of wet nights was observed (1.8 vs 4.1 for placebo).
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099902
03HumanNon-randomized trialEfficacy outcome
In adolescents receiving long-term desmopressin, 48% had 0 to 1 wet night per week in the first treatment period.
In plain wordsIn adolescents receiving desmopressin, 48% had at most one wet night weekly in the first long-term period.
Peptide
Desmopressin
Outcome
Not applicableResponders in first long-term period
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oral · 12 weeksAs given in this study (human).
Measurements
Responders
48%
first long-term period
Source sentences
Summary
During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week).
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099903
04HumanNon-randomized trialEfficacy outcome
In adolescents receiving long-term desmopressin, 53% had 0 to 1 wet night per week in the second treatment period.
In plain wordsIn adolescents receiving desmopressin, 53% had at most one wet night weekly in the second long-term period.
Peptide
Desmopressin
Outcome
Not applicableResponders in second long-term period
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oral · 12 weeksAs given in this study (human).
Measurements
Responders
53%
second long-term period
Source sentences
Summary
During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week).
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099904
05HumanNon-randomized trialEfficacy outcome
In adolescents receiving long-term desmopressin, 22% had 2 to 3 wet nights per week in the first period.
In plain wordsIn adolescents receiving desmopressin, 22% had two to three wet nights weekly in the first long-term period.
Peptide
Desmopressin
Outcome
Not applicableIntermediate responders in first long-term period
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oral · 12 weeksAs given in this study (human).
Measurements
Intermediate responders
22%
first long-term period
Source sentences
Summary
During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week).
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099905
06HumanNon-randomized trialEfficacy outcome
In adolescents receiving long-term desmopressin, 23.5% had 2 to 3 wet nights per week in the second period.
In plain wordsIn adolescents receiving desmopressin, 23.5% had two to three wet nights weekly in the second long-term period.
Peptide
Desmopressin
Outcome
Not applicableIntermediate responders in second long-term period
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oral · 12 weeksAs given in this study (human).
Measurements
Intermediate responders
23.5%
second long-term period
Source sentences
Summary
During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week).
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099906
07HumanNon-randomized trialSafety outcome
In adolescents receiving desmopressin for enuresis, no weight gain due to water retention occurred.
In plain wordsIn adolescents receiving desmopressin for bedwetting, no weight gain from water retention occurred.
Peptide
Desmopressin
Outcome
No significant changeWater-retention weight gain
Study
n: not reported in source
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
No weight gain was observed due to water retention.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099907
08HumanNon-randomized trialEfficacy outcome
After desmopressin cessation, 44% of adolescents had a significant decrease in wet nights.
In plain wordsAfter desmopressin stopped, 44% of adolescents had significantly fewer wet nights.
Peptide
Desmopressin
Outcome
DecreaseWet-night reduction after cessation
Study
n: not reported in source
Outcome group
Urinary Function · Kidney and urinary
Studied dose
Dose not stated · oralAs given in this study (human).
Measurements
Patients with reduction
44%
after cessation
Source sentences
Summary
After cessation of the drug, 44% of the patients had a significant decrease in the number of wet nights.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis.
Summary · context
The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo.
Summary · context
The final part was an open long-term study consisting of two 12-week treatment periods.
Report a problemFND-0797099908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.